Brief: Vir Biotechnology Grants Norgine Exclusive Commercial License To Chronic Hepatitis Delta Treatment Candidate
16/12/2025 21:19
Dec 16 (Reuters) - Vir Biotechnology Inc VIR.O: VIR BIOTECHNOLOGY GRANTS NORGINE EXCLUSIVE COMMERCIAL LICENSE TO CHRONIC HEPATITIS DELTA TREATMENT CANDIDATE IN EUROPE, AUSTRALIA & NEW ZEALAND, INCLUDING GLOBAL COST SHARING AGREEMENT FOR ONGOING ECLIPSE CLINICAL DEVELOPMENT PROGRAM VIR BIOTECHNOLOGY - TO RECEIVE EUR 55 MILLION INITIAL REIMBURSEMENT PAYMENT UPON CLOSING , EUR 495 MILLION IN CLINICAL, REGULATORY AND SALES MILESTONES VIR BIOTECHNOLOGY INC - NORGINE TO CONTRIBUTE 25% OF ECLIPSE PROGRAM COSTS VIR BIOTECHNOLOGY- EXPECTS CURRENT CASH, CASH EQUIVALENTS AND INVESTMENTS WILL BE EXTENDED INTO Q4 2027 Source text: ID:nBw4PtNkDa Further company coverage: VIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO